TEST:

SOPHiA Myeloid Plus Solution

"SOPHiA GENETICS...announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with SOPHiA GENETICS."

"SOPHiA GENETICS...announced an agreement with Hiroshima University...in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders...With NGS for myeloid testing not widely available in Japan, a group of Hiroshima University researchers tapped the SOPHiA DDM Platform to assist with the clinical utility of NGS tests for myeloid malignancies. Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms."